[Federal Register Volume 62, Number 39 (Thursday, February 27, 1997)]
[Notices]
[Pages 8973-8974]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-4959]
[[Page 8973]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Committees; Notice of Meetings
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces forthcoming meetings of public advisory
committees of the Food and Drug Administration (FDA). This notice also
summarizes the procedures for the meetings and methods by which
interested persons may participate in open public hearings before FDA's
advisory committees.
FDA has established an Advisory Committee Information Hotline (the
hotline) using a voice-mail telephone system. The hotline provides the
public with access to the most current information on FDA advisory
committee meetings. The advisory committee hotline, which will
disseminate current information and information updates, can be
accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory
committee is assigned a 5-digit number. This 5-digit number will appear
in each individual notice of meeting. The hotline will enable the
public to obtain information about a particular advisory committee by
using the committee's 5-digit number. Information in the hotline is
preliminary and may change before a meeting is actually held. The
hotline will be updated when such changes are made.
MEETINGS: The following advisory committee meetings are announced:
Blood Products Advisory Committee
Date, time, and place. March 13, 1997, 8 a.m., and March 14, 1997,
8:30 a.m., Quality Suites Hotel--Shady Grove, Potomac Rooms I, II, and
III, Three Research Ct., Rockville, MD.
Type of meeting and contact person. Open committee discussion,
March 13, 1997, 8 a.m. to 10:30 a.m.; open public hearing, 10:30 a.m.
to 11:30 a.m., unless public participation does not last that long;
open committee discussion, 11:30 a.m. to 2 p.m.; open public hearing, 2
p.m. to 2:30 p.m., unless public participation does not last that long;
open committee discussion, 2:30 p.m. to 4:30 p.m.; open public hearing,
4:30 p.m. to 5 p.m., unless public participation does not last that
long; open committee discussion, 5 p.m. to 5:30 p.m.; open committee
discussion, March 14, 1997, 8:30 a.m. to 10 a.m.; closed committee
discussion, 10 a.m. to 10:30 a.m.; Linda A. Smallwood, Office of Blood
Research and Review (HFM-350), Center for Biologics Evaluation and
Research, Food and Drug Administration, 1401 Rockville Pike, Rockville,
MD 20852-1448, 301-827-3514, or FDA Advisory Committee Information
Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area),
Blood Products Advisory Committee, code 12388. Please call the hotline
for information concerning any possible changes.
General function of the committee. The committee reviews and
evaluates data on the safety and effectiveness, and appropriate use of
blood products intended for use in the diagnosis, prevention, or
treatment of human diseases.
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person before March 7, 1997, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.
Open committee discussion. On the morning of March 13, 1997, the
committee will discuss nucleic acid testing of plasma pools. In the
afternoon, the committee will hear an informational report on the
reinvention of the Biologics License Application (BLA) for blood
products and have a discussion on the topic of patient notification. On
March 14, 1997, the committee will review the final report of the site
visit of the Laboratory of Plasma Derivatives, Division of Hematology,
Office of Blood Research and Review, Center for Biologics Evaluation
and Research.
Closed committee discussion. On March 14, 1997, the committee will
discuss confidential and personal privacy information relevant to the
scientific site visit report. This portion of the meeting will be
closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).
Anesthetic and Life Support Drugs Advisory Committee
Date, time, and place. March 24 and 25, 1997, 8:30 a.m., Holiday
Inn--Gaithersburg, Grand Ballroom, Two Montgomery Village Ave.,
Gaithersburg, MD.
Type of meeting and contact person. Open public hearing, March 24,
1997, 8:45 a.m. to 9:15 a.m., unless public participation does not last
that long; closed presentation of data, 9:15 a.m. to 1:30 p.m.; closed
committee deliberations, 1:30 p.m. to 5:30 p.m.; open public hearing,
March 25, 1997, 8:45 a.m. to 9:15 a.m., unless public participation
does not last that long; closed presentation of data, 9:15 a.m. to 1:30
p.m.; closed committee deliberations, 1:30 p.m. to 5 p.m.; Karen
Somers, Center for Drug Evaluation and Research (HFD-21), Food and Drug
Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455,
or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), Anesthetic and Life Support Drugs
Advisory Committee, code 12529. Please call the hotline for information
concerning any possible changes.
General function of the committee. The committee reviews and
evaluates data on the safety and effectiveness of marketed and
investigational human drugs for use in the field of anesthesiology and
surgery.
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person before March 14, 1997, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.
Closed presentation of data. The committee will hear trade secret
and/or confidential commercial information relevant to pending
investigational new drugs (IND's) and new drug applications (NDA's).
This portion of the meeting will be closed to permit discussion of this
information (5 U.S.C. 552b(c)(4)).
Closed committee deliberations. The committee will review trade
secret and/or confidential commercial information relevant to pending
IND's and NDA's. This portion of the meeting will be closed to permit
discussion of this information (5 U.S.C. 552b(c)(4)).
Each public advisory committee meeting listed above may have as
many as four separable portions: (1) An open public hearing, (2) an
open committee discussion, (3) a closed presentation of data, and (4) a
closed committee deliberation. Every advisory committee meeting shall
have an open public hearing portion. Whether or not it also includes
any of the other three portions will depend upon the specific meeting
involved. The dates and times reserved for the separate portions of
each committee meeting are listed above.
The open public hearing portion of the meeting(s) shall be at least
1 hour
[[Page 8974]]
long unless public participation does not last that long. It is
emphasized, however, that the 1 hour time limit for an open public
hearing represents a minimum rather than a maximum time for public
participation, and an open public hearing may last for whatever longer
period the committee chairperson determines will facilitate the
committee's work.
Public hearings are subject to FDA's guideline (subpart C of 21 CFR
part 10) concerning the policy and procedures for electronic media
coverage of FDA's public administrative proceedings, including hearings
before public advisory committees under 21 CFR part 14. Under 21 CFR
10.205, representatives of the electronic media may be permitted,
subject to certain limitations, to videotape, film, or otherwise record
FDA's public administrative proceedings, including presentations by
participants.
Meetings of advisory committees shall be conducted, insofar as is
practical, in accordance with the agenda published in this Federal
Register notice. Changes in the agenda will be announced at the
beginning of the open portion of a meeting.
Any interested person who wishes to be assured of the right to make
an oral presentation at the open public hearing portion of a meeting
shall inform the contact person listed above, either orally or in
writing, prior to the meeting. Any person attending the hearing who
does not in advance of the meeting request an opportunity to speak will
be allowed to make an oral presentation at the hearing's conclusion, if
time permits, at the chairperson's discretion.
The agenda, the questions to be addressed by the committee, and a
current list of committee members will be available at the meeting
location on the day of the meeting.
Transcripts of the open portion of the meeting may be requested in
writing from the Freedom of Information Office (HFI-35), Food and Drug
Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857,
approximately 15 working days after the meeting, at a cost of 10 cents
per page. The transcript may be viewed at the Dockets Management Branch
(HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23,
Rockville, MD 20857, approximately 15 working days after the meeting,
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary
minutes of the open portion of the meeting may be requested in writing
from the Freedom of Information Office (address above) beginning
approximately 90 days after the meeting.
The Commissioner has determined for the reasons stated that those
portions of the advisory committee meetings so designated in this
notice shall be closed. The Federal Advisory Committee Act (FACA) (5
U.S.C. app. 2, 10(d)), permits such closed advisory committee meetings
in certain circumstances. Those portions of a meeting designated as
closed, however, shall be closed for the shortest possible time,
consistent with the intent of the cited statutes.
The FACA, as amended, provides that a portion of a meeting may be
closed where the matter for discussion involves a trade secret;
commercial or financial information that is privileged or confidential;
information of a personal nature, disclosure of which would be a
clearly unwarranted invasion of personal privacy; investigatory files
compiled for law enforcement purposes; information the premature
disclosure of which would be likely to significantly frustrate
implementation of a proposed agency action; and information in certain
other instances not generally relevant to FDA matters.
Examples of portions of FDA advisory committee meetings that
ordinarily may be closed, where necessary and in accordance with FACA
criteria, include the review, discussion, and evaluation of drafts of
regulations or guidelines or similar preexisting internal agency
documents, but only if their premature disclosure is likely to
significantly frustrate implementation of proposed agency action;
review of trade secrets and confidential commercial or financial
information submitted to the agency; consideration of matters involving
investigatory files compiled for law enforcement purposes; and review
of matters, such as personnel records or individual patient records,
where disclosure would constitute a clearly unwarranted invasion of
personal privacy.
Examples of portions of FDA advisory committee meetings that
ordinarily shall not be closed include the review, discussion, and
evaluation of general preclinical and clinical test protocols and
procedures for a class of drugs or devices; consideration of labeling
requirements for a class of marketed drugs or devices; review of data
and information on specific investigational or marketed drugs and
devices that have previously been made public; presentation of any
other data or information that is not exempt from public disclosure
pursuant to the FACA, as amended; and, deliberation to formulate advice
and recommendations to the agency on matters that do not independently
justify closing.
This notice is issued under section 10(a)(1) and (a)(2) of the
Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations
(21 CFR part 14) on advisory committees.
Dated: February 24, 1997
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 97-4959 Filed 2-26-97; 8:45 am]
BILLING CODE 4160-01-F
